Krystal Biotech, Inc. Common Stock (KRYS) is a publicly traded Healthcare sector company. As of May 20, 2026, KRYS trades at $296.05 with a market cap of $8.60B and a P/E ratio of 38.58. KRYS moved +3.00% today. Year to date, KRYS is +23.43%; over the trailing twelve months it is +129.62%. Its 52-week range spans $122.80 to $319.48. Analyst consensus is strong buy with an average price target of $316.00. Rallies surfaces KRYS's financials, insider trades, hedge fund holdings, congressional trades, analyst ratings, and AI-generated research below.
Krystal Biotech, Inc. Common Stock (KRYS) research on Rallies includes live charts, financials, analyst ratings, hedge fund holdings, politician trades, insider activity, news, AI research, and community context. KRYS moved +3.00% today. Analyst consensus is strong buy.
| Metric | Value |
|---|---|
| Price | $296.05 |
| Market Cap | $8.60B |
| P/E Ratio | 38.58 |
| EPS | $7.75 |
| Dividend Yield | 0.00% |
| 52-Week High | $319.48 |
| 52-Week Low | $122.80 |
| Volume | 170.35K |
| Avg Volume | 0 |
| Revenue (TTM) | $417.30M |
| Net Income | $225.03M |
| Gross Margin | 0.00% |
10 analysts cover KRYS: 0 strong buy, 9 buy, 1 hold, 0 sell, 0 strong sell. Consensus rating is strong buy. Average price target: $316.00.